Spectrum Pharmaceuticals, Inc. announced that Mr. Tom Riga will join the company's board of directors effective December 31, 2021. Joseph Turgeon, President and CEO, have agreed that Mr. Turgeon will retire from Spectrum on December 31, 2021. Accordingly, he will also be stepping down from Spectrum?s Board of Directors. Mr. Riga joined the company in July 2013 as VP of Corporate Accounts and was named Chief Commercial Officer in August 2014 and Chief Operating Officer in December 2017. Mr. Riga has over 20 years of pharmaceutical leadership experience and has demonstrated a record of success in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. and Dendreon Pharmaceuticals LLC.